LAMC2 + Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3 / STAT3 / CD44 Axis
Cancer Science · 2026-11 · 117 (11) · 3071-3085
DOI: 10.1111/cas.70492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 05.08.2026. Verfasst von Yutong Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, STAT3 Transcription Factor, Hyaluronan Receptors, Laminin. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi Province, Key Research and Development Program of Shaanxi Provincial Health Commission.
Abstract (Originalsprache)
Laminin subunit gamma 2 (LAMC2) is a molecule related to the extracellular matrix. It plays a vital role in many cancers. But its effect in bladder cancer (BCa) is still undefined. This study was aimed at exploring the biological function, downstream mechanism, and therapeutic potential of LAMC2 in BCa. We combined single‐cell RNA sequencing data from 13 BCa samples and data from TCGA‐BLCA, GSE13507, and IMvigor210 cohorts. Bioinformatics analyses were carried out, including epithelial cell subclustering, pathway enrichment, GSVA, HdWGCNA, and RNA sequencing. The expression of LAMC2 in BCa tissues was confirmed through immunohistochemistry and immunofluorescence. Then shRNA was used to knock down LAMC2 in 5637 and T24 cells to test its effects in vitro and in vivo. These results were also tested in a xenograft tumor model. Potential inhibitors of LAMC2 were screened by molecular docking and in vitro experiments. We found that LAMC2 was enriched in a malignant epithelial cell subgroup and was linked to higher tumor grade, advanced tumor stage, poor prognosis and inferior response to immunotherapy. LAMC2 regulated bladder cancer cell proliferation, migration, and invasion through the SerpinB3/STAT3/CD44 axis based on the results of in vitro and single‐cell analysis. Diosmetin was found to suppress LAMC2‐related signaling in bladder cancer cells, providing a new strategy for BCa treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Vascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Jianpeng Li, Jinhai Fan
Förderung
- National Natural Science Foundation of China
- Natural Science Basic Research Program of Shaanxi Province
- Key Research and Development Program of Shaanxi Provincial Health Commission
Zitieren
APA
Chen, Y., Jiang, Y., Yang, Z., Jing, M., Wu, W., He, J., Wang, L., Ma, M., Zhang, Y., Wang, M., Li, J., Pu, Y., He, B., Liu, Y., Mi, K., Liu, H., Zhang, M., & Fan, J. (2026). LAMC2 + Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3 / STAT3 / CD44 Axis. Cancer Science, 117(11), 3071-3085. https://doi.org/10.1111/cas.70492
Vancouver
Chen Y, Jiang Y, Yang Z, Jing M, Wu W, He J, et al. LAMC2 + Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3 / STAT3 / CD44 Axis. Cancer Science. 2026;117(11):3071-3085. doi:10.1111/cas.70492
BibTeX
@article{Chen2026,
author = {Chen, Yutong and Jiang, Yunzhong and Yang, Zezhong and Jing, Minxuan and Wu, Wentai and He, Jiale and Wang, Lu and Ma, Minghai and Zhang, Yaodong and Wang, Min and Li, Jianpeng and Pu, Yuanchun and He, Bingliang and Liu, Yanjia and Mi, Kaibo and Liu, Hang and Zhang, Mengzhao and Fan, Jinhai},
title = {LAMC2 + Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3 / STAT3 / CD44 Axis},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {11},
pages = {3071--3085},
doi = {10.1111/cas.70492}
}
EUVIMED